Evelo Biosciences Provides Clinical and Business Updates
– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed –
– Clear path to registration trials for EDP1815 in psoriasis based on recently completed interactions with FDA, EMA and MHRA –
– Dosing commenced in clinical study with first extracellular vesicle (EV) product candidate EDP2939 in January; Phase 2 data in psoriasis anticipated in 2H 2023 –
– Optimizing operations and reducing workforce to focus resources on strategic priorities –
– CEO Simba Gill, Ph.D., will continue to lead the organization, halting search for successor –
– Management to host conference call today at 8:30 a.m. ET –
Related news for (EVLO)
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
- Evelo Biosciences Closes $25.5 Million Private Placement
- Evelo Biosciences Announces $25.5 Million Private Placement